Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma

Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and has fewer severe side effects than other agents used for that purpose. However, due to a lack of tumor-specific targeting, the concentration of the drug in tumor tissue cannot be permanently maintained at a level that i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xiaolong, Chen, Longzhou, Li, Amin, Cai, Shiyu, Zhang, Yinci, Liu, Xueke, Jiang, Zhenyou, Liu, Xinkuang, Liang, Yong, Ma, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058710/
https://www.ncbi.nlm.nih.gov/pubmed/29916268
http://dx.doi.org/10.1080/10717544.2018.1477859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058710/
https://www.ncbi.nlm.nih.gov/pubmed/29916268
http://dx.doi.org/10.1080/10717544.2018.1477859

Ejemplares similares